Physician profile
Camilo A Rincon
NPI 1033206453
$2,262.81
in general payments reported to CMS, 2019-2025
22 companies · $95.76 in 2025
The $95.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $321 · 2021: $592 · 2022: $691 · 2023: $215 · 2024: $185 · 2025: $95.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $544.17 | 2019-2025 | |
| Abbvie INC. | $303.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.36 | 2021-2025 | |
| Novo Nordisk INC | $192.67 | 2021-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $169.41 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.06 | 2021-2022 | |
| Lilly USA, LLC | $115.11 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $114.80 | 2021-2025 | Farxiga, Breztri, Lokelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.97 | 2019-2022 | |
| Allergan, INC. | $66.96 | 2019-2020 | |
| Orexo US, INC. | $55.28 | 2019-2020 | |
| Indivior INC. | $46.84 | 2019-2023 | Sublocade |
| Sanofi-Aventis U.S. LLC | $36.01 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $24.07 | 2020 | |
| Exact Sciences Corporation | $23.34 | 2023 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $14.48 | 2021 | |
| Glaxosmithkline, LLC. | $14.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.98 | 2021 | |
| Gilead Sciences, INC. | $13.32 | 2023 | |
| Almatica Pharma LLC | $11.57 | 2021 | |
| Cvrx, INC. | $11.14 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilo Rincon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.